Clinical Trial

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-18; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2026-02-27
Trial Details
NCT Number NCT07249905
Lead Sponsor ModeX Therapeutics, An OPKO Health Company
Conditions Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL, HGBCL, FL Lymphoma, Lymphoplasmacytic Lymphoma, Follicular Lymphoma (FL)
Enrollment 180 participants
Start Date 2026-04-13
Primary Completion 2028-01 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-04